Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY: GKOS )

153.20 +6.82 (+4.66%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Glaukos Announces Second Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
7 Leading MedTech Stocks for Next-Gen Health Solutions
With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar. 
Via InvestorPlace
10 Analysts Have This To Say About Glaukos
Via Benzinga
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31
From Glaukos Corporation
Via Business Wire
Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)
Via Benzinga
Analyst Ratings For Glaukos
Via Benzinga
5 Analysts Have This To Say About Glaukos
Via Benzinga
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst
Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%. 
Via Benzinga
Topics Earnings
Exposures Financial
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Glaukos: Q4 Earnings Insights
Via Benzinga
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024
GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Glaukos Announces First Quarter 2024 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Announces the Release of its 2023 Sustainability Report
From Glaukos Corporation
Via Business Wire
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
From Glaukos Corporation
Via Business Wire
Earnings Scheduled For February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
Analyst Ratings For Glaukos
Via Benzinga
Unveiling 7 Analyst Insights On Glaukos
Via Benzinga
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
From Glaukos Corporation
Via Business Wire
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
From Glaukos Corporation
Via Business Wire
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
From Glaukos Corporation
Via Business Wire
Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst
Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S. 
Via Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.